Skip to content

Author

Yong Fang

We have 2 of 269 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Nov 2026

Expert consensus on the diagnosis and treatment of EGFR gene mutation non-small cell lung cancer

Abstract Background: Epidermal growth factor receptor (EGFR) mutations are the most clinically actionable oncogenic drivers in Asian patients with non-small-cell lung cancer (NSCLC). The therapeutic landscape has rapidly evolved from single-agent EGFR tyrosine kinase inhibitors (TKIs) to risk-adapted first-line intensi...

R. Meng, Chun-Wei Xu, Wen-Xian Wang et al. · 0 citations
Open access Aug 2026

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

Osimertinib plus chemotherapy significantly increased progression-free survival among patients with EGFR-mutated advanced NSCLC harboring concurrent TP53 mutations, and provided a clinical rationale for individualized combination strategies in the management of patients with EGFR-mutated NSCLC.

Ting Zhou, Huaqiang Zhou, Fangfang Gao et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.